PSTV_OUT_1 [2025-04-01 04:11:57 -0400] 2387 Bytes | 769 tokens | Cum: 769 tkns (9.61% of 8k)
==========================================================================

Listen up, partner—it's 4:11:56 AM on Tue Apr 01, 2025 -0400, and I’m revved up about PLUS THERAPEUTICS (PSTV), climbing from 0.9501 to 1.1. This stock is buzzing big-time—do we have a hidden gem, or a flash in the pan? Help me sift through the data!

Here's the first list of news for PLUS THERAPEUTICS:

C1 - Mar-28-25 01:12PM - Q4 2024 Plus Therapeutics Inc Earnings Call
C2 - Mar-28-25 01:12PM 03:04AM - Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ...
C3 - Mar-27-25 07:42PM - Plus Therapeutics, Inc. (PSTV) Q4 2024 Earnings Call Transcript
C4 - Mar-27-25 07:42PM 05:35PM - Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates
C5 - Mar-27-25 07:42PM 04:05PM - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
C6 - Mar-21-25 12:17PM - PSTV Stock Surges as FDA Accepts Proprietary Name for Lead Drug
C7 - Mar-21-25 12:17PM 06:34AM - Why Plus Therapeutics Inc. (PSTV) Surged On Thursday?
C8 - Mar-20-25 07:30AM - Plus Therapeutics Introduces REYOBIQ , FDA-Accepted Proprietary Name for Lead Drug Candidate

Prior AI Reports for PSTV:
1. 2025-03-25 – Score: 70 – Target: 2.1600 – Highs: 1.5700 / 1.5600 / 1.77
plus-therapeutics-sees-momentum-amid-sales-growth-and-performance-spike
2. 2025-03-24 – Score: 65 – Target: 2.2000 – Highs: 1.5000 / 1.5700 / 1.56
pstv-shows-strong-sales-growth-amid-debt-concerns
3. 2025-03-20 – Score: 45 – Target: 0.7500 – Highs: 2.0800 / 1.3500 / 1.50
no-available-headline-for-this-report

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on PLUS THERAPEUTICS (PSTV)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PSTV_OUT_3 [2025-04-01 04:12:00 -0400] 441 Bytes | 152 tokens | Cum: 923 tkns (11.54% of 8k)
==========================================================================

Showing C4 (chunk 1 of 1): C4:
**Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates**
Date: Mar-27-25 07:42PM 05:35PM
Source: (Zacks)
URL: /news/12018/plus-therapeutics-pstv-reports-q4-loss-misses-revenue-estimates

**No additional content available.**

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PSTV_OUT_5 [2025-04-01 04:12:00 -0400] 995 Bytes | 293 tokens | Cum: 1249 tkns (15.61% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-03-31T21:05:46Z - 12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adver...
A2 - 2025-03-28T07:04:47Z - Plus Therapeutics Inc (PSTV) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ......
A3 - 2025-03-27T22:39:00Z - Plus Therapeutics (PSTV) Reports Q4 Loss, Misses Revenue Estimates...
A4 - 2025-03-27T21:05:49Z - 12 Health Care Stocks Moving In Thursday's After-Market Session - Equillium (NASDAQ:EQ), Edap TMS (N...
A5 - 2025-03-27T20:26:48Z - Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Hi...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PSTV_OUT_7 [2025-04-01 04:12:06 -0400] 1098 Bytes | 337 tokens | Cum: 1588 tkns (19.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 4): A1:
**12 Health Care Stocks Moving In Monday's After-Market Session - AquaBounty Techs (NASDAQ:AQB), Adverum Biotechnologies (NASDAQ:ADVM)**Date: 2025-03-31Source: {'uri': 'benzinga.com', 'dataType': 'news', 'title': 'Benzinga'}URL: https://www.benzinga.com/insights/movers/25/03/44573149/12-health-care-stocks-moving-in-mondays-after-market-sessionGainers bioAffinity Technologies BIAF stock rose 198.8% to $0.78 during Monday's after-market session. The company's market cap stands at $12.1 million. As per the press release, Q4 earnings came out today. Nutex Health NUTX shares rose 51.02% to $70.3. The company's market cap stands at $382.2 million. As per the press release, Q4 earnings came out today. Compass Therapeutics CMPX stock rose 18.42% to $2.25. The company's market cap stands at $309.5 million. Plus Therapeutics PSTV stock moved upwards by 17.7% to $1.13. The market value of their

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PSTV_OUT_9 [2025-04-01 04:12:07 -0400] 988 Bytes | 286 tokens | Cum: 2033 tkns (25.41% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2025-03-04T19:06:00Z - Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
B2 - 2024-07-02T11:30:00Z - Plus Therapeutics to Present at the Gordon Research Conference Radionuclide Theranostics for the Management of Cancer
B3 - 2024-06-07T11:30:00Z - Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
B4 - 2024-05-17T21:00:00Z - Plus Therapeutics Announces New Employment Inducement Grants
B5 - 2024-05-15T20:15:00Z - Plus Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
B6 - 2024-05-13T11:30:00Z - Plus Therapeutics to Announce First Quarter Financial Results and Host Conference Call on May 15, 2024

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PSTV_OUT_11 [2025-04-01 04:12:09 -0400] 746 Bytes | 197 tokens | Cum: 2232 tkns (27.90% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2025/03/04/3036891/0/en/Plus-Therapeutics-Secures-Private-Placement-of-Approximately-15-Million-in-Gross-Proceeds.htmlPlus Therapeutics, a clinical-stage pharmaceutical company, announced the pricing of a $15.0 million private placement. The funds will be used to advance the company's central nervous system cancer therapies and meet key near-term milestones.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PSTV_OUT_13 [2025-04-01 04:12:10 -0400] 1078 Bytes | 273 tokens | Cum: 2553 tkns (31.91% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper

Our Mgts Discussion and Analysis of Fin Cond and Results of Oper includes the following sections:

Overview that discusses our business.

Results of Operati...

S2 - 2025-03-27 8-K Item 2.02 Results of Oper and Fin Cond.

On March 27, 2025, Plus Therapeutics, Inc. (the Company) reported financial results for the fourth quarter and year ended December 31, 2024 and other recent corporate updates. A copy of the press release is furnished as E...

S3 - 2025-03-04 8-K Item1.01 Entry Into a Material Definitive Agrmt.

Private Placement

On March 4, 2025, Plus Therapeutics, Inc. (the Company) entered into a securities purchase agreement (the Securities Purchase Agrmt) with accredited investors, including certain existing stockholders o...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PSTV_OUT_15 [2025-04-01 04:12:18 -0400] 1098 Bytes | 275 tokens | Cum: 2830 tkns (35.38% of 8k)
==========================================================================

Showing S2 (chunk 1 of 2): S2:
Item 2.02 Results of Operations and Financial Condition.

On March 27, 2025, Plus Therapeutics, Inc. (the Company) reported financial results for the fourth quarter and year ended December 31, 2024 and other recent corporate updates. A copy of the press release is furnished as Exhibit 99.1 to this report and incorporated by reference.

The information in this Item 2.02 of this Current Report on Form 8-K (including Exhibit 99.1) is furnished and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after todays date, regardless of any general incorp

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PSTV_OUT_17 [2025-04-01 04:12:27 -0400] 4507 Bytes | 1313 tokens | Cum: 4265 tkns (53.31% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+------------------------+------------------------+
| Volume: 3,525,604 | Perf Month: 31.05% | Option/Short: No / No | Sales Y/Y TTM: 18.54% |
+--------------------+-----------------------+------------------------+------------------------+
| Avg Volume: 15.92M | Perf Quarter: -12.03% | Short Float: 8.10% | ROE: - |
+--------------------+-----------------------+------------------------+------------------------+
| Rel Volume: 0.22 | Index: - | Short Ratio: 0.06 | ROI: - |
+--------------------+-----------------------+------------------------+------------------------+
| RSI (14): 47.22 | Market Cap: 11.20M | Short Interest: 0.93M | Sales Surprise: -6.40% |
+--------------------+-----------------------+------------------------+------------------------+
| ATR (14): 0.35 | Shs Outstand: 11.79M | Beta: 0.50 | EPS Surprise: -55.02% |
+--------------------+-----------------------+------------------------+------------------------+
| SMA20: -9.02% | Shs Float: 11.48M | Sales Q/Q: 7.54% | P/E: - |
+--------------------+-----------------------+------------------------+------------------------+
| SMA50: -13.84% | Inst Own: 16.02% | Sales past 5Y: 383.24% | Earnings: Mar 27 AMC |
+--------------------+-----------------------+------------------------+------------------------+
| SMA200: -30.05% | Insider Own: 2.55% | Employees: - | |
+--------------------+-----------------------+------------------------+------------------------+
| Perf Week: -16.66% | Insider Trans: 0.00% | Debt/Eq: - | |
+--------------------+-----------------------+------------------------+------------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Hawkins Richard J (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

Inside Trans: PLUS THERAPEUTICS, INC. (PSTV) by Clowes Howard (Unknown Title) on 2025-02-18
- Stock Option (Right to Buy): 40122 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 1456000.0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -2874000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.9501
Average Volume: 46284438.71
30-Day High: 1.57
30-Day Low: 0.3022

[Detailed Financials: Q3 2024]
- Total Assets: $6,978,000.0
- Total Liabilities: $12,152,000.0
- Total Equity: $-5,174,000.0
- Current Assets: $5,364,000.0
- Current Liabilities: $12,112,000.0

[Income Statement: Q3 2024]
- Revenue: $1,456,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.37

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-3,689,000.0

[Detailed Financials: Q2 2024]
- Total Assets: $11,212,000.0
- Total Liabilities: $18,837,000.0
- Total Equity: $-7,625,000.0
- Current Assets: $9,380,000.0
- Current Liabilities: $18,787,000.0

[Income Statement: Q2 2024]
- Revenue: $1,279,000.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.45

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $2,011,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PSTV_OUT_19 [2025-04-01 04:12:30 -0400] 676 Bytes | 167 tokens | Cum: 4705 tkns (58.81% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PSTV_IN_21 [2025-04-01 04:12:30 -0400] 126 Bytes | 29 tokens | Cum: 4810 tkns (60.12% of 8k)
==========================================================================

====================================
[2025-04-01 04:12:30] # Analysis Completed
Elapsed Time: 34.15 seconds